Back when Pascal Soriot took charge at the then-troubled AstraZeneca (LSE: AZN) in 2012, I didn’t expect a quick fix. No, it was going to take time, money and hard work to get the drugs giant’s development pipeline flowing again. But the market reacted with a rare long-term outlook, and the AstraZeneca share price gradually strengthened.
AstraZeneca shares have almost trebled since Soriot took up the CEO position, while the FTSE 100 has put on just 25%. It helps that AstraZeneca fared relatively well during the pandemic-induced crash. But I can’t help being concerned over one specific question. Has enthusiasm overtaken reality?
I’m talking about valuation here, and how AstraZeneca’s starting to make me suck my teeth and shake my head a bit. The thing is, while the shares have been climbing, earnings haven’t.
Well, EPS did rise in 2020. But there were several years of falling earnings prior to that, with a collapse from more than $4 in 2017, to barely above $1 in 2019. The $2.44 per share recorded in 2020 was a welcome uptick, but it was still way below levels of old.
AstraZeneca share price valuation
Years of weakening earnings, coupled with an accelerating share price, mean only one thing. And that’s a ballooning P/E valuation. On the current AstraZeneca share price, and based on trailing 2020 earnings, we’re looking at a multiple of a shade under 50 now.
Going on forecasts, the forward figure still stands at a little over 40. That’s up in a small-cap growth stock territory, for a FTSE 100 company with a market-cap of more than £133bn.
It doesn’t necessarily mean it’s overvalued. But it does mean AstraZeneca will need to grow its earnings substantially to get that P/E down closer to the Footsie’s average. I’m not suggesting AstraZeneca is an average company that should be on an average valuation. No, better companies can often sustain significantly higher valuations.
But to get the AstraZeneca P/E down only as far as 20, earnings would need to climb to around 430p. That’s close to 2.5 times 2020 earnings.
Is such earnings growth achievable? I think it is. The real question in my mind is how long will it take? While good news is coming in steadily, investors are usually happy to hold on, and even keep buying.
But all it can take is one set of figures that don’t quite meet the latest elevated expectations, and suddenly we can see a whole host of sellers dumping their shares. Even a quiet spell on the news front can push some away.
And even though Covid-related sales only contribute a tiny portion of the company’s profits, the general pharmaceuticals sector bullishness surely helped lift the AstraZeneca share price. And that effect has to end, eventually.
So what’s the bottom line for me? I think AstraZeneca is an excellent company with the potential to generate profits and dividends for many years to come. And it’s one I’d definitely like to have in my Stocks & Shares ISA.
I just hesitate at the current valuation. I’ll watch, and maybe buy on the dips.
Markets around the world are reeling from the coronavirus pandemic…
And with so many great companies still trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.
But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.
Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…
You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.
That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.
Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.